Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab
Some phase 2 trials had reported encouraging progression-free survival with Bevacizumab in monotherapy or combined with chemotherapy in glioblastoma. However, phase 3 trials showed a significant improvement in progression free survival without a benefit in overall survival. To date, there are no predictive biomarker of response for Bevacizumab in glioblastoma.
We used Immunochemical analysis on tumor samples and pretreatment and post-treatment perfusion-MRI to try to identify possible predictive angiogenesis-related biomarkers of response and survival in patients with glioblastoma treated with bevacizumab in the first recurrence. We analyzed histological parameters: vascular proliferation, mitotic number and Ki-67 index; molecular factors: MGMT promoter methylation, EGFR amplification and EGFR variant III; immunohistochemical: MET, Midkine, HIF1, VEGFA, VEGF-R2, CD44, Olig2, microvascular area and microvascular density; and radiological: rCBV.
In the statistical analysis, no significant correlation of any histological, molecular, microvascular or radiological parameters could be demonstrated with the response rate, PFS or OS with bevacizumab treatment.
Unfortunately, in this histopathological, molecular, immunohistochemical and neuroradiological study we did not find any predictive biomarker of response or survival benefit for Bevacizumab in glioblastoma.
KeywordsBevacizumab Glioblastoma Biomarkers Microvacular density Microvascular area
Dr. RAMK project conception, project organization, project execution and writing first draft. Dr. JMS project conception, project organization, project execution, manuscript review and critique. Dr. YR project execution. Dr. OT project execution. Dr. AP: project conception, manuscript review and critique. DC project execution. Dr. AH: project conception, imaging, manuscript review. Dr. AR: project execution, imaging. Dr. VOR project execution. Dr. PS project conception, project organization, project execution, manuscript review and critique. Dr. AH project conception, project organization, project execution, manuscript review and critique.
This work was supported by a grant from the GEINO (Spanish Group for Research in Neurooncology) and a Grant number PI/13/01258 from ISCIII and co-funded with the European Regional Development Funds.
Compliance with ethical standards
Conflict of interest
Dr. Manneh Kopp reports no disclosures. Dr. Sepúlveda-Sánchez reports no disclosures. Dr. Ruano reports no disclosures. Dr. Toldos reports no disclosures. Dr. Perez-Nuñez reports no disclosures. Diana Cantero reports no disclosures. Dr. Hilario reports no disclosures. Dr. Ramos reports no disclosures. Dr. Velasco Oria de Rueda reports no disclosures. Dr. Sánchez-Gómez reports no disclosures. Dr. Hernandez-Lain reports no disclosures.
- 3.Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol. 2008;26:271–8.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Chinot O, Wick W, Mason W, et al. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in AVAGlio. Neuro-Oncology. 2012;14(Suppl 6):vi101–vi105.Google Scholar
- 8.Wick W, Brandes AA, Gorlia T, et al. EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma. J Clin Oncol. 2001;34(suppl):abstr.Google Scholar
- 10.Pakalniskis MG, Wells WA, Schwab MC, Froehlich HM, Jiang S, Li Z, et al. Tumor angiogenesis change estimated by using diffuse optical spectroscopic tomography: demonstrated correlation in women undergoing neoadjuvant chemotherapy for invasive breast cancer? Radiology. 2011;259:365–74.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Hilario A, Sepulveda JM, Hernandez-Lain A, Salvador E, Koren L, Manneh R, et al. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab. Clin Transl Oncol. 2017;19:51–7.CrossRefPubMedGoogle Scholar
- 18.Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000;1(60):5954–8.Google Scholar
- 23.Baumgarten P, Blank AE, Franz K, Hattingen E, Dunst M, Zeiner P, et al. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas. Neuro Oncol. 2016;18:173–83.CrossRefPubMedGoogle Scholar
- 27.Schmainda KM, Prah M, Connelly J, Rand SD, Hoffman RG, et al. Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. NeuroOncol. 2014;16:880–8.Google Scholar
- 33.Molina D, Pérez-Beteta J, Martínez-González A, Sepúlveda JM, Peralta S, Gil-Gil MJ, et al. Geometrical measures obtained from pretreatment postcontrast T1 weighted MRIs predict survival benefits from bevacizumab in glioblastoma patients. PLoS ONE. 2016;11(8):e0161484.CrossRefPubMedPubMedCentralGoogle Scholar